| 0.8267 0.04 (5.12%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.17 | 1-year : | 1.41 |
| Resists | First : | 1 | Second : | 1.21 |
| Pivot price | 0.82  |
|||
| Supports | First : | 0.66 | Second : | 0.55 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.87 |
| MA(100) : | 7.23 |
MA(250) : | 73.6 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 26.1 |
D(3) : | 26.1 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 209.5 | Low : | 0.66 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ONCO ] has closed above bottom band by 28.4%. Bollinger Bands are 96.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 72 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.8 | 0.8 - 0.8 |
| Low: | 0.74 - 0.75 | 0.75 - 0.75 |
| Close: | 0.76 - 0.77 | 0.77 - 0.78 |
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Wed, 29 Jul 2026
ONCO|Onconetix Inc|Price:0.683|Chg%:-0.066 - TradingKey
Wed, 29 Jul 2026
Why Is Onco Micro-Cap Stock Surging 50% In Premarket? - Stocktwits
Mon, 27 Jul 2026
Onconetix, Inc. announced that it expects to receive $780.2496 million in funding - marketscreener.com
Mon, 27 Jul 2026
Onconetix (ONCO) 13G: Keystone Capital reports 6.1% beneficial stake - Stock Titan
Sat, 25 Jul 2026
Onconetix, Inc. Revenue Breakdown – NASDAQ:ONCO - TradingView
Fri, 24 Jul 2026
ONCO Stock Price, Quote & Chart - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -6 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.69e+006 (%) |
| Held by Institutions | 1.15e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.77e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 377.39 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 748.7 % |
| Return on Equity (ttm) | -25.3 % |
| Qtrly Rev. Growth | 735200 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 10.82 |
| Price to Cash Flow | 0 |
| Dividend | 122240 |
| Forward Dividend | 18630 |
| Dividend Yield | 15871200% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|